<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">phkinetica</journal-id><journal-title-group><journal-title xml:lang="ru">Фармакокинетика и Фармакодинамика</journal-title><trans-title-group xml:lang="en"><trans-title>Pharmacokinetics and Pharmacodynamics</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2587-7836</issn><issn pub-type="epub">2686-8830</issn><publisher><publisher-name>ООО «Издательство ОКИ»</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.37489/2587-7836-2025-4-32-41</article-id><article-id custom-type="elpub" pub-id-type="custom">phkinetica-483</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>МЕХАНИЗМ ДЕЙСТВИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>MECHANISM OF ACTION</subject></subj-group></article-categories><title-group><article-title>Оптимизация условий экспериментальных моделей, опосредованных нарушением ГАМК-ергической нейропередачи</article-title><trans-title-group xml:lang="en"><trans-title>The optimization of experimental models mediated by impaired gabaergic neurotransmission</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-1065-8899</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Шангин</surname><given-names>С. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Shangin</surname><given-names>S. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Шангин Станислав Владимирович — м. н. с. лаборатории молекулярной фармакологии</p><p>Москва</p></bio><bio xml:lang="en"><p>Stanislav V. Shangin — Junior Researcher at the Laboratory of Molecular Pharmacology</p><p>Moscow</p></bio><email xlink:type="simple">shangin_sv@academpharm.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-8946-2989</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Мариевский</surname><given-names>В. Е.</given-names></name><name name-style="western" xml:lang="en"><surname>Marievskii</surname><given-names>V. E.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Мариевский Валентин Евгеньвич — м. н. с. лаборатории молекулярной фармакологии</p><p>Москва</p></bio><bio xml:lang="en"><p>Valentin E. Marievskii — Junior Researcher at the Laboratory of Molecular Pharmacology</p><p>Moscow</p></bio><email xlink:type="simple">marievskii_ve@academpharm.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-7062-8261</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Вахитова</surname><given-names>Ю. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Vakhitova</surname><given-names>Yu. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Вахитова Юлия Венеровна — д. б. н., член-корр. РАН; ФГАОУ ВО РНИМУ им. Н.И. Пирогова Минздрава России (Пироговский Университет)</p><p>Москва</p></bio><bio xml:lang="en"><p>Yulia V. Vakhitova — PhD, Dr. Sci. (Biology), RAS corresponding member, N.I. Pirogov Russian National Research Medical University</p><p>Moscow</p></bio><email xlink:type="simple">juvv73@gmail.com</email><xref ref-type="aff" rid="aff-2"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГБНУ «ФИЦ оригинальных и перспективных биомедицинских и фармацевтических технологий»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Federal research center for innovator and emerging biomedical and pharmaceutical technologies</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>ФГАОУ ВО «Российский национальный исследовательский медицинский университет имени Н.И. Пирогова»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>N.I. Pirogov Russian National Research Medical University</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2025</year></pub-date><pub-date pub-type="epub"><day>30</day><month>12</month><year>2025</year></pub-date><volume>0</volume><issue>4</issue><fpage>32</fpage><lpage>41</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Шангин С.В., Мариевский В.Е., Вахитова Ю.В., 2026</copyright-statement><copyright-year>2026</copyright-year><copyright-holder xml:lang="ru">Шангин С.В., Мариевский В.Е., Вахитова Ю.В.</copyright-holder><copyright-holder xml:lang="en">Shangin S.V., Marievskii V.E., Vakhitova Y.V.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.pharmacokinetica.ru/jour/article/view/483">https://www.pharmacokinetica.ru/jour/article/view/483</self-uri><abstract><sec><title>Актуальность</title><p>Актуальность. Эпилепсия представляет собой одно из наиболее распространённых неврологических заболеваний, в основе которого лежит нарушение баланса между возбуждающей и тормозной нейропередачей в центральной нервной системе. В связи с этим оптимизация условий используемых в настоящее время моделей судорог, отражающих патофизиологию эпилепсии, для оценки эффективности потенциальных лекарственных средств остаётся актуальной задачей экспериментальной фармакологии.</p></sec><sec><title>Цель работы</title><p>Цель работы. Оптимизация условий трёх экспериментальных моделей судорог, индуцированных внутривенным введением конвульсантов с различными механизмами действия, для последующей фармакологической оценки противосудорожной и просудорожной активностей.</p></sec><sec><title>Материалы и методы</title><p>Материалы и методы. Для индукции эпилепсии внутривенно в боковую хвостовую вену при постоянной скорости вводили пентилентетразол, бикукуллин или пикротоксин мышам ICR. Порог судорог определяли в соответствии с минимальной дозой конвульсантов. Клонические подергивания, генерализованные клонические судороги и генерализованные тонические судороги регистрировали с помощью видеокамеры с дальнейшей оценкой.</p></sec><sec><title>Результаты</title><p>Результаты. По результатам экспериментов для моделей пентилентетразол-, бикукуллин- и пикротоксин-индуцированных судорог установлены оптимальные параметры введения, обеспечивающие воспроизводимость и чувствительность к противосудорожным препаратам. Оптимальность условий введения конвульсантов для моделей подтверждается демонстрацией дозозависимого противосудорожного эффекта диазепама, который статистически значимо повышает судорожный порог и замедляет развитие приступа во всех моделях судорог.</p></sec><sec><title>Заключение</title><p>Заключение. В результате проведённого исследования были определены оптимальные условия введения конвульсантов с различными механизмами действия на трёх экспериментальных моделях судорог. Полученные результаты могут быть использованы для последующих доклинических исследований потенциальных соединений, обладающих противосудорожным действием.</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>Relevance</title><p>Relevance. Epilepsy is one of the most common neurological diseases, which is based on a disregulation of the balance between excitatory and inhibitory neurotransmission in the central nervous system. In this regard, the optimization of conditions for the currently used seizure models that reﬂect the pathophysiology of epilepsy, for the evaluation of the eﬃcacy of potential drugs, remains a relevant task in experimental pharmacology.</p></sec><sec><title>Objective</title><p>Objective. Optimization of the conditions of three experimental seizure models induced by intravenous administration of convulsants with diﬀerent mechanisms of action for subsequent pharmacological evaluation of anticonvulsant and pro-convulsive activities.</p></sec><sec><title>Materials and methods</title><p>Materials and methods. Epilepsy was induced in ICR mice by intravenous administration of pentylenetetrazol, bicuculline, or picrotoxin into the lateral tail vein at a constant rate. The seizure threshold was determined as the minimum dose of convulsants. Clonic seizures, generalized clonic seizures, and generalized tonic seizures were recorded using a video camera with subsequent evaluation.</p></sec><sec><title>Results</title><p>Results. Based on the experimental results, optimal administration parameters were established for models of pentylenetetrazole, bicuculline, and picrotoxin-induced seizures, ensuring reproducibility and sensitivity to anticonvulsants. The optimality of the convulsant administration conditions for the models is conﬁrmed by the demonstration of a dose-dependent anticonvulsant eﬀect of diazepam, which statistically signiﬁcantly increases the seizure threshold and slows the development of a seizure in all models.</p></sec><sec><title>Conclusion</title><p>Conclusion. As a result of this study, the optimal conditions for the administration of convulsants with diﬀerent mechanisms of action were determined for three experimental seizure models. The obtained results can be used for subsequent preclinical studies of potential compounds possessing anticonvulsant activity.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>эпилепсия</kwd><kwd>судороги</kwd><kwd>пентилентетразол</kwd><kwd>бикукуллин</kwd><kwd>пикротоксин</kwd><kwd>диазепам</kwd><kwd>мыши</kwd></kwd-group><kwd-group xml:lang="en"><kwd>epilepsy</kwd><kwd>seizures</kwd><kwd>pentylenetetrazole</kwd><kwd>bicuculline</kwd><kwd>picrotoxin</kwd><kwd>diazepam</kwd><kwd>mice</kwd></kwd-group><funding-group><funding-statement xml:lang="ru">Работа выполнена в рамках государственного задания Министерства науки и высшего образования Российской Федерации № FGFG-2025-0004.</funding-statement><funding-statement xml:lang="en">This work was conducted under the government contracts of the Ministry of Science and Higher Education of the Russian Federation (Project FGFG- 2025-0004).</funding-statement></funding-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">van van Hugte EJH, Schubert D, Nadif Kasri N. Excitatory/inhibitory balance in epilepsies and neurodevelopmental disorders: Depolarizing aminobutyric acid as a common mechanism. Epilepsia. 2023 Aug;64(8):1975-1990. doi: 10.1111/epi.17651.</mixed-citation><mixed-citation xml:lang="en">van van Hugte EJH, Schubert D, Nadif Kasri N. Excitatory/inhibitory balance in epilepsies and neurodevelopmental disorders: Depolarizing aminobutyric acid as a common mechanism. Epilepsia. 2023 Aug;64(8):1975-1990. doi: 10.1111/epi.17651.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Zhai W, Yu Q, Wu H. The efficacy and safety of novel antiepileptic drugs in treatment of epilepsy of patients with brain tumors. Front Neurol. 2024 Mar 7;15:1344775. doi: 10.3389/fneur.2024.1344775.</mixed-citation><mixed-citation xml:lang="en">Zhai W, Yu Q, Wu H. The efficacy and safety of novel antiepileptic drugs in treatment of epilepsy of patients with brain tumors. Front Neurol. 2024 Mar 7;15:1344775. doi: 10.3389/fneur.2024.1344775.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Appleton RE, Freeman A, Cross JH. Diagnosis and management of the epilepsies in children: a summary of the partial update of the 2012 NICE epilepsy guideline. Arch Dis Child. 2012 Dec;97(12):1073-6. doi: 10.1136/archdischild-2012-302822.</mixed-citation><mixed-citation xml:lang="en">Appleton RE, Freeman A, Cross JH. Diagnosis and management of the epilepsies in children: a summary of the partial update of the 2012 NICE epilepsy guideline. Arch Dis Child. 2012 Dec;97(12):1073-6. doi: 10.1136/archdischild-2012-302822.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Руководство по проведению доклинических исследований лекарственных средств. Часть первая. М.: Гриф и К, 2012. 944 с.</mixed-citation><mixed-citation xml:lang="en">Guidelines for conducting preclinical studies of medicinal products. Part one. Moscow: Grif and K, 2012 (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Shangin SV, Vakhitova YV, Litvinova SA, et al. Anticonvulsant Properties of Fabomotizole When Administered Separately and in Conjunction with Diazepam. Pharm Chem J. 2025;59:711-716. doi: 10.1007/s11094-025-03445-6.</mixed-citation><mixed-citation xml:lang="en">Shangin SV, Vakhitova YV, Litvinova SA, et al. Anticonvulsant Properties of Fabomotizole When Administered Separately and in Conjunction with Diazepam. Pharm Chem J. 2025;59:711-716. doi: 10.1007/s11094-025-03445-6.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Voronin MV, Shangin SV, Litvinova SA, et al. Pharmacological Analysis of GABAA Receptor and Sigma1R Chaperone Interaction: Research Report I-Investigation of the Anxiolytic, Anticonvulsant and Hypnotic Effects of Allosteric GABAA Receptors' Ligands. Int J Mol Sci. 2023 May 31;24(11):9580. doi: 10.3390/ijms24119580.</mixed-citation><mixed-citation xml:lang="en">Voronin MV, Shangin SV, Litvinova SA, et al. Pharmacological Analysis of GABAA Receptor and Sigma1R Chaperone Interaction: Research Report I-Investigation of the Anxiolytic, Anticonvulsant and Hypnotic Effects of Allosteric GABAA Receptors' Ligands. Int J Mol Sci. 2023 May 31;24(11):9580. doi: 10.3390/ijms24119580.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Socała K, Wlaź P. Acute seizure tests used in epilepsy research: Stepby-step protocol of the maximal electroshock seizure (MES) test, the maximal electroshock seizure threshold (MEST) test, and the pentylenetetrazole (PTZ)-induced seizure test in rodents. Experimental and translational methods to screen drugs effective against seizures and epilepsy. 2021;167:79-102. doi: 10.1007/978-1-0716-1254-5_5.</mixed-citation><mixed-citation xml:lang="en">Socała K, Wlaź P. Acute seizure tests used in epilepsy research: Stepby-step protocol of the maximal electroshock seizure (MES) test, the maximal electroshock seizure threshold (MEST) test, and the pentylenetetrazole (PTZ)-induced seizure test in rodents. Experimental and translational methods to screen drugs effective against seizures and epilepsy. 2021;167:79-102. doi: 10.1007/978-1-0716-1254-5_5.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Bukanova JV, Kondratenko RV, Solntseva EI. Positive allosteric modulators of GABAA receptor restore chloride current from blockade by competitive antagonists in a ligand-dependent manner. J Steroid Biochem Mol Biol. 2022 Nov;224:106158. doi: 10.1016/j.jsbmb.2022.106158.</mixed-citation><mixed-citation xml:lang="en">Bukanova JV, Kondratenko RV, Solntseva EI. Positive allosteric modulators of GABAA receptor restore chloride current from blockade by competitive antagonists in a ligand-dependent manner. J Steroid Biochem Mol Biol. 2022 Nov;224:106158. doi: 10.1016/j.jsbmb.2022.106158.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">MacDonald RL, Rogers CJ, Twyman RE. Barbiturate regulation of kinetic properties of the GABAA receptor channel of mouse spinal neurones in culture. J Physiol. 1989 Oct;417:483-500. doi: 10.1113/jphysiol.1989.sp017814.</mixed-citation><mixed-citation xml:lang="en">MacDonald RL, Rogers CJ, Twyman RE. Barbiturate regulation of kinetic properties of the GABAA receptor channel of mouse spinal neurones in culture. J Physiol. 1989 Oct;417:483-500. doi: 10.1113/jphysiol.1989.sp017814.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Cully M. GABAA receptor structures solved. Nat Rev Drug Discov. 2019 Feb;18(2):98. doi: 10.1038/d41573-019-00002-1.</mixed-citation><mixed-citation xml:lang="en">Cully M. GABAA receptor structures solved. Nat Rev Drug Discov. 2019 Feb;18(2):98. doi: 10.1038/d41573-019-00002-1.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Ghit A, Assal D, Al-Shami AS, Hussein DEE. GABAA receptors: structure, function, pharmacology, and related disorders. J Genet Eng Biotechnol. 2021 Aug 21;19(1):123. doi: 10.1186/s43141-021-00224-0.</mixed-citation><mixed-citation xml:lang="en">Ghit A, Assal D, Al-Shami AS, Hussein DEE. GABAA receptors: structure, function, pharmacology, and related disorders. J Genet Eng Biotechnol. 2021 Aug 21;19(1):123. doi: 10.1186/s43141-021-00224-0.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Pressly B, Vasylieva N, Barnych B, et al. Comparison of the toxicokinetics of the convulsants picrotoxinin and tetramethy lenedisulfotetramine (TETS) in mice. Arch Toxicol. 2020 Jun;94(6):1995-2007. doi: 10.1007/s00204-020-02728-z.</mixed-citation><mixed-citation xml:lang="en">Pressly B, Vasylieva N, Barnych B, et al. Comparison of the toxicokinetics of the convulsants picrotoxinin and tetramethy lenedisulfotetramine (TETS) in mice. Arch Toxicol. 2020 Jun;94(6):1995-2007. doi: 10.1007/s00204-020-02728-z.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Seutin V, Scuvée-Moreau J, Dresse A. Evidence for a non-GABAergic action of quaternary salts of bicuculline on dopaminergic neurones. Neuropharmacology. 1997 Nov-Dec;36(11-12):1653-7. doi: 10.1016/s0028-3908(97)00147-0.</mixed-citation><mixed-citation xml:lang="en">Seutin V, Scuvée-Moreau J, Dresse A. Evidence for a non-GABAergic action of quaternary salts of bicuculline on dopaminergic neurones. Neuropharmacology. 1997 Nov-Dec;36(11-12):1653-7. doi: 10.1016/s0028-3908(97)00147-0.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Hoyberghs J, Bars C, Ayuso M, et al. DMSO Concentrations up to 1 % are Safe to be Used in the Zebrafish Embryo Developmental Toxicity Assay. Front Toxicol. 2021 Dec 21;3:804033. doi: 10.3389/ftox.2021.804033.</mixed-citation><mixed-citation xml:lang="en">Hoyberghs J, Bars C, Ayuso M, et al. DMSO Concentrations up to 1 % are Safe to be Used in the Zebrafish Embryo Developmental Toxicity Assay. Front Toxicol. 2021 Dec 21;3:804033. doi: 10.3389/ftox.2021.804033.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Bastami Z, Soltanpour S, Panahi-Azar V, Jouyban A. Solubility of clonazepam and diazepam in binary and ternary mixtures of polyethylene glycols 400 or 600, propylene glycol and water at 298.2 K-experimental data and modeling. Journal of the Serbian Chemical Society. 2014;79(4):445-56 doi: 10.2298/JSC121212079B.</mixed-citation><mixed-citation xml:lang="en">Bastami Z, Soltanpour S, Panahi-Azar V, Jouyban A. Solubility of clonazepam and diazepam in binary and ternary mixtures of polyethylene glycols 400 or 600, propylene glycol and water at 298.2 K-experimental data and modeling. Journal of the Serbian Chemical Society. 2014;79(4):445-56 doi: 10.2298/JSC121212079B.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">van Eenige R, Verhave PS, Koemans PJ, et al. RandoMice, a novel, user-friendly randomization tool in animal research. PLoS One. 2020 Aug 5; 5(8):e0237096. doi: 10.1371/journal.pone.0237096.</mixed-citation><mixed-citation xml:lang="en">van Eenige R, Verhave PS, Koemans PJ, et al. RandoMice, a novel, user-friendly randomization tool in animal research. PLoS One. 2020 Aug 5; 5(8):e0237096. doi: 10.1371/journal.pone.0237096.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Hedrich H, Bullock G. The Laboratory Mouse: Part of the Handbook of Experimental Animals By Contributor: Academic Press; 2004. ISBN 0-12-336425-6</mixed-citation><mixed-citation xml:lang="en">Hedrich H, Bullock G. The Laboratory Mouse: Part of the Handbook of Experimental Animals By Contributor: Academic Press; 2004. ISBN 0-12-336425-6</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Greenfield EA. Sampling and Preparation of Mouse and Rat Serum. Cold Spring Harb Protoc. 2017 Nov 1;2017(11):pdb.prot100271. doi: 10.1101/pdb.prot100271</mixed-citation><mixed-citation xml:lang="en">Greenfield EA. Sampling and Preparation of Mouse and Rat Serum. Cold Spring Harb Protoc. 2017 Nov 1;2017(11):pdb.prot100271. doi: 10.1101/pdb.prot100271</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Van Erum J, Van Dam D, De Deyn PP. PTZ-induced seizures in mice require a revised Racine scale. Epilepsy Behav. 2019 Jun;95:51-55. doi: 10.1016/j.yebeh.2019.02.029.</mixed-citation><mixed-citation xml:lang="en">Van Erum J, Van Dam D, De Deyn PP. PTZ-induced seizures in mice require a revised Racine scale. Epilepsy Behav. 2019 Jun;95:51-55. doi: 10.1016/j.yebeh.2019.02.029.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Vavers E, Svalbe B, Lauberte L, et al. The activity of selective sigma-1 receptor ligands in seizure models in vivo. Behav Brain Res. 2017 Jun 15;328:13-18. doi: 10.1016/j.bbr.2017.04.008.</mixed-citation><mixed-citation xml:lang="en">Vavers E, Svalbe B, Lauberte L, et al. The activity of selective sigma-1 receptor ligands in seizure models in vivo. Behav Brain Res. 2017 Jun 15;328:13-18. doi: 10.1016/j.bbr.2017.04.008.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Bernardi G, Marciani MG, Morucutti C, Giacomini P. The action of picrotoxin and bicuculline on rat caudate neurons inhibited by GABA. Brain Res. 1976 Feb 6;102(2):379-84. doi: 10.1016/0006-8993(76)90896-9</mixed-citation><mixed-citation xml:lang="en">Bernardi G, Marciani MG, Morucutti C, Giacomini P. The action of picrotoxin and bicuculline on rat caudate neurons inhibited by GABA. Brain Res. 1976 Feb 6;102(2):379-84. doi: 10.1016/0006-8993(76)90896-9</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Сергиенко В.И., Бондарева И.Б., Маевский Е.И. Методические рекомендации по статистической обработке результатов доклинических исследований лекарственных средств. Руководство по проведению доклинических исследований лекарственных средств. Часть первая. М.: Гриф и К, 2012; Глава 61:889-929.</mixed-citation><mixed-citation xml:lang="en">Sergienko VI, Bondareva IB, Maevsky EI. Guidelines for Statistical Analysis of Preclinical Drug Research Results. Guidelines for conducting preclinical studies of medicinal products. Part one. Moscow: Grif and K, 2012; Chapter 61:889-929. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Löscher W, Nolting B. The role of technical, biological and pharmacological factors in the laboratory evaluation of anticonvulsant drugs. IV. Protective indices. Epilepsy Res. 1991 May-Jun;9(1):1-10. doi: 10.1016/0920-1211(91)90041-d.</mixed-citation><mixed-citation xml:lang="en">Löscher W, Nolting B. The role of technical, biological and pharmacological factors in the laboratory evaluation of anticonvulsant drugs. IV. Protective indices. Epilepsy Res. 1991 May-Jun;9(1):1-10. doi: 10.1016/0920-1211(91)90041-d.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Mazarati AM, Baldwin R, Klitgaard H, et al. Anticonvulsant effects of levetiracetam and levetiracetam-diazepam combinations in experimental status epilepticus. Epilepsy Res. 2004 Feb;58(2-3):167-74. doi: 10.1016/j.eplepsyres.2004.02.002.</mixed-citation><mixed-citation xml:lang="en">Mazarati AM, Baldwin R, Klitgaard H, et al. Anticonvulsant effects of levetiracetam and levetiracetam-diazepam combinations in experimental status epilepticus. Epilepsy Res. 2004 Feb;58(2-3):167-74. doi: 10.1016/j.eplepsyres.2004.02.002.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru"></mixed-citation><mixed-citation xml:lang="en"></mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
